Resistin and cardiovascular pathology


DOI: https://dx.doi.org/10.18565/therapy.2021.9.137-147

Alieva A.M., Baykova I.E., Khadzhieva N.H., Ettinger O.A., Arakelyan R.А., Valiev R.K., Rakhaev A.M., Batov М.А., Elmurzaeva D.А., Malkarova D.S., Nikitin I.G.

1) N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 2) Central Clinical Hospital ««RZHD-Meditsina», Moscow; 3) A.S. Loginov Moscow Clinical Research Center of the Healthcare Department of Moscow; 4) Kh.M. Berbekov Kabardino-Balkarian State University of the Ministry of Science and Higher Education of Russia, Nalchik; 5) P.A. Herzen Moscow Research Institute of Oncology – a branch of National Medical Research Center for Radiology
Abstract. In the modern world, it remains relevant to search for and study new biological markers that can help early diagnosis of cardiovascular diseases, serve as a laboratory tool for assessing the effectiveness of therapy, be a prognostic marker of possible adverse clinical outcomes and a significant criterion for risk stratification. The purpose of this review is to consider resistin as a diagnostic and prognostic marker in cardiovascular pathology based on the analysis of foreign and domestic literature sources from the PubMed, RSCI, MedLine, Google Scholar, Science Direct databases. Many studies have described such functions of resistin as metabolism of glucose and lipids in the blood, modulation of satiety centers in somatotrophic cells of the hypothalamus and pituitary gland, regulation of the central nervous system, synthesis and secretion of various pro-inflammatory cytokines and differentiation of monocytes into macrophages, effect on heart contractility, angiogenesis , smooth muscle cell activity and kidney function. Blood resistin levels in healthy people are in the range of 7–22 ng/ml (average 15 ng/ml). Further work is required to determine the specific resistin receptor, which will subsequently lead to the identification of specific signaling pathways and will help clarify the role of this biological marker in type 2 diabetes mellitus, dyslipidemia, and cardiovascular diseases.
Keywords: resistin, insulin resistance, cardiovascular diseases, diabetes mellitus, metabolic syndrome
Read entire article

Literature


  1. Алиева А.М., Резник Е.В., Гасанова Э.Т. с соавт. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018; 5: 333–345. [Alieva A.M., Reznik E.V., Hasanova E.T. et al. Clinical significance of the determination of blood biomarkers in patients with chronic heart failure. Arkhiv vnutrenney meditsiny = Archive of Internal Medicine. 2018; 5: 333–345 (In Russ.)]. http://dx.doi.org/10.20514/2226-6704-2018-8-5-333-345.

  2. Алиева А.М., Байкова И.Е., Кисляков В.А. с соавт. Галектин-3: диагностическая и прогностическая ценность определения у пациентов с хронической сердечной недостаточностью. Терапевтический архив. 2019; 9: 145–149. [Aliyeva A.M., Baykova I.E., Kislyakov V.A. et al. Galactin-3: diagnostic and prognostic value in patients with chronic heart failure. Terapevticheskiy arkhiv = Therapeutic Archive. 2019; 9: 145–149 (In Russ.)]. http://dx.doi.org/10.26442/00403660.2019.09.000226.

  3. Алиева А.М., Пинчук Т.В., Алмазова И.И. с соавт. Клиническое значение определения биомаркера крови ST2 у больных с хронической сердечной недостаточностью. Consilium Medicum. 2021; 6: 522–526. [Alieva A.M., Pinchuk T.V., Almazova I.I. et al. Сlinical value of blood biomarker ST2 in patients with chronic heart failure. Consilium Medicum. 2021; 23(6): 522–526 (In Russ.)]. http://dx.doi.org/10.26442/20751753.2021.6.200606.

  4. Rachwalik M., Hurkacz M., Sienkiewicz-Oleszkiewicz B., Jasinski M. Role of resistin in cardiovascular diseases: Implications for prevention and treatment. Adv Clin Exp Med. 2021; 30(8): 865–74. doi: 10.17219/acem/135978.

  5. Steppan C.M., Bailey S.T., Bhat S. et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307–12. doi:10.1038/35053000.

  6. Steppan C.M., Brown E.J., Wright C.M. et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A. 2001; 98(2): 502–06. doi: 10.1073/pnas.98.2.502.

  7. Park H.K., Kwak M.K., Kim H.J., Ahima R.S. Linking resistin, inflammation, and cardiometabolic diseases. Korean J Intern Med. 2017; 32(2): 239–47. doi: 10.3904/kjim.2016.229.

  8. Deb A., Deshmukh B., Ramteke P. et al. Resistin: A journey from metabolism to cancer. Transl Oncol. 2021; 14(10): 101178. doi: 10.1016/j.tranon.2021.101178.

  9. Kim M., Oh J.K., Sakata S. et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008; 45(2): 270–80. doi: 10.1016/j.yjmcc.2008.05.006.

  10. Hu Q., Tan H., Irwin D. Evolution of the vertebrate resistin gene family. PLoS One. 2015; 10(6): e0130188. doi: 10.1371/journal.pone.0130188.

  11. Hannan A.F., Culligan K.G. Human resistin and the RELM of inflammation in diabesity. Diabetol Metab Syndr. 2015; 7: 54. doi: 10.1186/s13098-015-0050-3.

  12. Borsuk A., Biernat W., Zieba D. Multidirectional action of resistin in the organism. Postep Hig Med Dosw. 2018; 72: 327–38.

  13. Codoner-Franch P., Alonso-Iglesias E. Resistin: Insulin resistance to malignancy. Clin Chim Acta. 2015; 438: 46–54. doi: 10.1016/j.cca.2014.07.043.

  14. Acquarone E., Monacelli F., Borghi R. et al. Resistin: A reappraisal. Mech Ageing Dev. 2019; 178: 46–63. doi: 10.1016/j.mad.2019.01.004.

  15. Hasenour C.M., Berglund E.D., Wasserman D.H. Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver. Mol Cell Endocrinol. 2013; 366(2): 152–62. doi: 10.1016/j.mce.2012.06.018.

  16. Benomar Y., Gertler A., De Lacy P. et al. Central resistin overexposure induces insulin resistance through Toll-like receptor 4. Diabetes. 2013; 62(1): 102–14. doi: 10.2337/db12-0237.

  17. Gong W.J., Liu J.Y., Yin J.Y. et al. Resistin facilitates metastasis of lung adenocarcinoma through the TLR4/Src/EGFR/PI3K/NF-κB pathway. Cancer Sci. 2018; 109(8): 2391–400. doi: 10.1111/cas.13704.

  18. Chen S.S., Tang C.H., Chie M.J. et al. Resistin facilitates VEGF-A-dependent angiogenesis by inhibiting miR-16-5p in human chondrosarcoma cells. Cell Death Dis. 2019; 10(1): 31. doi: 10.1038/s41419-018-1241-2.

  19. Ramteke P., Deb A., Shepal V., Bhat M.K. Hyperglycemia associated metabolic and molecular alterations in cancer risk, progression, treatment, and mortality. Cancers (Basel). 2019; 11(9): 1402. doi: 10.3390/cancers11091402.

  20. Wang C.H., Wang P.J., Hsieh Y.C. et al. Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene. 2018; 37(5): 589–600. doi: 10.1038/onc.2017.357.

  21. Sudan S.K., Deshmukh S.K., Poosarla T. et al. Resistin: An inflammatory cytokine with multi-faceted roles in cancer. Biochim Biophys Acta Rev Cancer. 2020; 1874(2): 188419. doi: 10.1016/j.bbcan.2020.188419.

  22. Badoer E. Cardiovascular and metabolic crosstalk in the brain: Leptin and resistin. Front Physiol. 2021; 12: 639417. doi: 10.3389/fphys.2021.639417.

  23. Вербовой А.Ф., Цанава И.А., Шаронова Л.А. Резистин: биологические и патофизиологические эффекты. Клиническая медицина. 2017; 4: 322–327. [Verbovoy A.F., Tsanava I.A., Sharonova L.A. Resistin: biological and pathophysiological effects. Klinicheskaya meditsina = Clinical medicine. 2017; 4: 322–327 (In Russ.)]. http://dx.doi.org/10.18821/0023-2149-2017-95-4-322-327.

  24. Lazar M.A. Resistin- and obesity-associated metabolic diseases. Horm Metab Res. 2007; 39(10): 710–16. doi: 10.1055/s-2007-985897.

  25. Song R., Wang X., Mao Y. et al. Resistin disrupts glycogen synthesis under high insulin and high glucose levels by down-regulating the hepatic levels of GSK3β. Gene. 2013; 529(1): 50–56. doi: 10.1016/j.gene.2013.06.085.

  26. Schwartz D.R., Lazar M.A. Human resistin: Found in translation from mouse to man. Trends Endocrinol Metab. 2011; 22(7): 259–65. doi: 10.1016/j.tem.2011.03.005.

  27. Daquinag A.C., Zhang Y., Amaya-Manzanares F. et al. An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell. 2011; 9(1): 74–86. doi: 10.1016/j.stem.2011.05.017.

  28. Sanchez-Solana B., Laborda J., Baladron V. Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol Endocrinol. 2012; 26(1): 110–27. doi: 10.1210/me.2011-1027.

  29. Satoh H., Nguyen M.T., Miles P.D. et al. Adenovirus-mediated chronic «hyper-resistinemia» leads to in vivo insulin resistance in normal rats. J Clin Invest. 2004; 114(2): 224–31. doi: 10.1172/JCI20785.

  30. Zieba D.A., Biernat W., Barc J. Roles of leptin and resistin in metabolism, reproduction, and leptin resistance. Domest Anim Endocrinol. 2020; 73: 106472. doi: 10.1016/j.domaniend.2020.106472.

  31. Wang C.Q., Tang C.H., Tzeng H.E. et al. Impacts of RETN genetic polymorphism on breast cancer development. J Cancer. 2020; 11(10): 2769–77. doi:10.7150/jca.38088.

  32. Park H.K., Ahima R.S. Resistin in rodents and humans. Diabetes Metab J. 2013; 37(6): 404–14. doi: 10.4093/dmj.2013.37.6.404.

  33. Jamaluddin M.S., Yan S., Lü J. et al. Resistin increases monolayer permeability of human coronary artery endothelial cells. PLoS One. 2013; 8(12): e84576. doi: 10.1371/journal.pone.0084576.

  34. Jamaluddin M.S., Weakley S.M., Yao Q., Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012; 165(3): 622–32. doi: 10.1111/j.1476-5381.2011.01369. x.

  35. Kumar S., Gupta V., Srivastava N. et al. Resistin 420C/G gene polymorphism on circulating resistin, metabolic risk factors and insulin resistance in adult women. Immunol Lett. 2014; 162(2 Pt B): 287–91. doi: 10.1016/j.imlet.2014.07.009.

  36. Qatanani M., Szwergold N.R., Greaves D.R. et al. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest. 2009; 119(3): 531–39. doi: 10.1172/JCI37273.

  37. Park H.K., Qatanani M., Briggs E.R. et al. Inflammatory induction of human resistin causes insulin resistance in endotoxemic mice. Diabetes. 2011; 60(3): 775–83. doi: 10.2337/db10-1416.

  38. Sheng C.H., Du Z.W., Song Y. et al. Human resistin inhibits myogenic differentiation and induces insulin resistance in myocytes. Biomed Res Int. 2013; 2013: 804632. doi: 10.1155/2013/804632.

  39. Pastusiak K., Kregielska-Narozna M., Bogdanski P. Resistin is not a useful insulin resistance marker for non-obese patients. J Physiol Pharmacol. 2020; 71(3). doi: 10.26402/jpp.2020.3.06.

  40. Yan Y., Yang X., Zhao T. et al. The association between serum resistin and PPARγ Pro12Ala polymorphism in patients with gestational diabetes mellitus. Pak J Pharm Sci. 2020; 33(6): 2553–56.

  41. Zhang J., Gao Y., Zheng Y.Y. et al. Increased serum resistin level is associated with coronary heart disease. Oncotarget. 2017; 8(30): 50148–54. doi: 10.18632/oncotarget.15707.

  42. Perovic E., Mrdjen A., Harapin M. et al. Diagnostic and prognostic role of resistin and copeptin in acute ischemic stroke. Top Stroke Rehabil. 2017; 24(8): 614–18. doi: 10.1080/10749357.2017.1367454.

  43. Ramirez J.L., Khetani S.A., Zahner G.J. et al. Serum resistin is associated with impaired endothelial function and a higher rate of adverse cardiac events in patients with peripheral artery disease. J Vasc Surg. 2019; 69(2): 497–506. doi: 10.1016/j.jvs.2018.05.251.

  44. Chae C.W., Kwon Y.W. Cell signaling and biological pathway in cardiovascular diseases. Arch Pharm Res. 2019; 42(3): 195–205. doi: 10.1007/s12272-019-01141-0.

  45. Niaz S., Latif J., Hussain S. Serum resistin: A possible link between inflammation, hypertension and coronary artery disease. Pak J Med Sci. 2019; 35(3): 641–46. doi: 10.12669/pjms.35.3.274.

  46. Rashid S., Khurshid R., Amir U.F. et al. A novel link between adipokines and lipoprotein (a) to contemplate their diagnostic role in patients with stemi and nstemi. J Ayub Med Coll Abbottabad. 2017; 29(1): 112–17.

  47. Khera A.V., Qamar A., Murphy S.A. et al. On-statin resistin, leptin, and risk of recurrent coronary events after hospitalization for an acute coronary syndrome (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 study). Am J Cardiol. 2015; 116(5): 694–98. doi: 10.1016/j.amjcard.2015.05.038.

  48. Pourmoghaddas A., Elahifar A., Darabi F. et al. Resistin and prooxidant-antioxidant balance: Markers to discriminate acute coronary syndrome from stable angina. ARYA Atheroscler. 2020; 16(2): 46–54. doi: 10.22122/arya. v16i2.1944.

  49. Muse E.D., Feldman D.I., Blaha M.J. et al. The association of resistin with cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2015; 239(1): 101–08. doi: 10.1016/j.atherosclerosis.2014.12.044.

  50. Chemaly E.R., Hadri L., Zhang S. et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol. 2011; 51(2): 144–55. doi: 10.1016/j.yjmcc.2011.04.006.

  51. Rothwell S.E., Richards A.M., Pemberton C.J. Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun. 2006; 349(1): 400–07. doi: 10.1016/j.bbrc.2006.08.052.

  52. Schwartz D.R., Briggs E.R., Qatanani M. et al. Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer. Endocrinology. 2013; 154(11): 4206–14. doi: 10.1210/en.2013-1399.

  53. Ghanem S.E., Abdel-Samiee M., Torky M.H. et al. Role of resistin, IL-6 and NH2-terminal portion proBNP in the pathogenesis of cardiac disease in type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2020; 8(1): e001206. doi: 10.1136/bmjdrc-2020-001206.

  54. Puchałowicz K., Kłoda K., Dziedziejko V. et al. Association of adiponectin, leptin and resistin plasma concentrations with echocardiographic parameters in patients with coronary artery disease. Diagnostics (Basel). 2021; 11(10): 1774. doi: 10.3390/diagnostics11101774.

  55. Farcas A.D., Rusu A., Stoia M.A., Vida-Simiti L.A. Plasma leptin, but not resistin, TNF-α and adiponectin, is associated with echocardiographic parameters of cardiac remodeling in patients with coronary artery disease. Cytokine. 2018; 103: 46–49. doi: 10.1016/j.cyto.2018.01.002.

  56. Авсарагова А.З., Астахова З.Т., Ремизов О.В. Влияние адипокина резистина на риск развития сердечно-сосудистых осложнений у больных с острым коронарным синдромом. Вестник новых медицинских технологий. 2019; 4: 49–52. [Avsaragova A.Z., Astakhova Z.T., Remizov O.V. Effect of adipokine resistin on the risk of cardiovascular complications in patients with acute coronary syndrome. Vestnik novykh meditsinskikh tekhnologiy = Bulletin of New Medical Technologies. 2019; 4: 49–52 (In Russ.)]. https://dx.doi.org/10.24411/1609-2163-2019-16513.

  57. Norata G.D., Ongari M., Garlaschelli K. et al. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol. 2007; 156(2): 279–84. doi: 10.1530/eje.1.02338.

  58. Singh A.K., Tiwari S., Gupta A. et al. Association of resistin with metabolic syndrome in Indian subjects. Metab Syndr Relat Disord. 2012; 10(4): 286–91. doi: 10.1089/met.2011.0128.

  59. Cabrera de Leon A., Almeida Gonzalez D., Gonzalez Hernandez A. et al. Relationships between serum resistin and fat intake, serum lipid concentrations and adiposity in the general population. J Atheroscler Thromb. 2014; 21(5): 454–62. doi: 10.5551/jat.22103.

  60. Costandi J., Melone M., Zhao A., Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ Res. 2011; 108(6): 727–42. doi: 10.1161/CIRCRESAHA.110.238949.

  61. Rashid S., Kastelein J.J. PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia. Expert Rev Cardiovasc Ther. 2013; 11(11): 1567–77. doi: 10.1586/14779072.2013.839204.

  62. Melone M., Wilsie L., Palyha O. et al. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol. 2012; 59(19): 1697–705. doi: 10.1016/j.jacc.2011.11.064.

  63. Li S., Xu R.X., Zhang Y. et al. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status. J Endocrinol Invest. 2015; 38(12): 1291–99. doi: 10.1007/s40618-015-0310-y.

  64. Kosari S., Rathner J.A., Chen F. et al. Centrally administered resistin enhances sympathetic nerve activity to the hindlimb but attenuates the activity to brown adipose tissue. Endocrinology. 2011; 152(7): 2626–33. doi: 10.1210/en.2010-1492.

  65. Badoer E., Kosari S., Stebbing M.J. Resistin, an adipokine with non-generalized actions on sympathetic nerve activity. Front Physiol. 2015; 6: 321. doi: 10.3389/fphys.2015.00321.

  66. Thomopoulos C., Daskalaki M., Papazachou O. et al. Association of resistin and adiponectin with different clinical blood pressure phenotypes. J Hum Hypertens. 2011; 25(1): 38–46. doi: 10.1038/jhh.2010.22.

  67. Papadopoulos D.P., Makris T.K., Perrea D. et al. Adiponectin–insulin and resistin plasma levels in young healthy offspring of patients with essential hypertension. Blood Press. 2008; 17(1): 50–54. doi: 10.1080/08037050701876307.

  68. Zhang L., Curhan G.C., Forman J.P. Plasma resistin levels associate with risk for hypertension among nondiabetic women. J Am Soc Nephrol. 2010; 21(7): 1185–91. doi: 10.1681/ASN.2009101053.

  69. Chandrasekaran S., Hunt H., Melhorn S. et al. Adipokine profiles in preeclampsia. J Matern Fetal Neonatal Med. 2020; 33(16): 2812–817. doi: 10.1080/14767058.2018.1562542.

  70. Bawah A.T., Yeboah F.A., Nanga S. et al. Serum adipocytokines and adiposity as predictive indices of preeclampsia. Clin Hypertens. 2020; 26: 19. doi: 10.1186/s40885-020-00152-0.

  71. Шулькина С.Г. Гендерные особенности уровня лептина, растворимых рецепторов лептина и резистина у больных артериальной гипертензией, ассоциированной с ожирением. Пермский медицинский журнал. 2016; 2: 44–49. [Shulkina S.G. Gender characteristics of the level of leptin, soluble receptors of leptin and resistin in patients with arterial hypertension associated with obesity. Permskiy meditsinskiy zhurnal = Perm Medical Journal. 2016; 2: 44–49 (In Russ.)].

  72. Yuxiang L., Fujiu K. Human resistin and cardiovascular disease. Int Heart J. 2020; 61(3): 421–23. doi: 10.1536/ihj.20-221.


About the Autors

Amina M. Alieva, PhD, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: amisha_alieva@mail.ru. ORCID: 0000-0001-5416-8579. SPIN-code: 2749-6427
Irina E. Baykova, PhD, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: 1498553@mail.ru. ORCID: 0000-0003-0886-6290. SPIN-code: 3054-8884
Nyurzhanna H. Khadzhieva, obstetrician-gynecologist at Central Clinical Hospital «RZHD-Meditsina». Address: 107078, Moscow, 5 Novaya Basmannaya Str. E-mail: nurzhanna@yandex.ru
Olga A. Ettinger, PhD, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: olga-oett@mail.ru. ORCID: 0000-0002-1237-3731
Roza A. Arakelyan, student of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: Elmira.sharm@yandex.ru
Ramiz K. Valiev, PhD, head of the Department of oncosurgery No. 2, A.S. Loginov Moscow Clinical Research Center of the Healthcare Department of Moscow. Address: 111123, Moscow, 86 Entuziastov Highway. E-mail: Radiosurgery@bk.ru. ORCID: 0000-0003-1613-3716. SPIN-code: 2855-2867
Alik M. Rakhaev, MD, professor of the Department of children’s diseases, obstetrics and gynecology of the Faculty of general medicine, Kh.M. Berbekov Kabardino-Balkarian State University of the Ministry of Science and Higher Education of Russia. Address: 360004, Nalchik, 173 Chernyshevskogo Str. Е-mail: alikrahaev@yandex.ru
Maxim A. Batov, resident physician at P.A. Herzen Moscow Research Institute of Oncology – a branch of National Medical Research Center for Radiology. Address: 125284, Moscow, 3 2nd Botkinsky Drive. E-mail: m.batov112@gmail.com. ORCID: 0000-0002-3780-4358. SPIN-code: 5850-7711
Dzhannet A. Elmurzaeva, PhD, associate professor of the Department of microbiology, virology and immunology of the Faculty of medicine, Kh.M. Berbekov Kabardino-Balkarian State University of the Ministry of Science and Higher Education of Russia. Address: 360004, Nalchik, 173 Chernyshevskogo Str. E-mail: jannet.elmurzaeva@yandex.ru. ORCID: 0000-0002-5640-6638. SPIN-код: 7284-3749.
Darina S. Malkarova, 6th year student of the Faculty of medicine, Kh.M. Berbekov Kabardino-Balkarian State University of the Ministry of Science and Higher Education of Russia. Address: 360004, Nalchik, 173 Chernyshevskogo Str.
Igor G. Nikitin, MD, professor, head of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: igor.nikitin.64@mail.ru. ORCID: 0000-0003-1699-0881


Similar Articles

Back to Content

Бионика Медиа